Insights on Tildrakizumab: Durability and Safety

Aaron S. Farberg, MD, is an assistant professor of dermatology and a dermatologic surgeon at Baylor University Medical Center in Dallas, TX. Dr Farberg is, also, the lead editor for a book on technology in skin cancer and has been a clinical investigator in many studies with some being FDA clinical trials. He has been recognized with numerous awards and honors in addition to having published more than 70 articles in medical journals. In this video, Dr Farberg discusses his insights on tildrakizumab’s durability and safety following his poster presentation at AAD 2021.

Transcript:

Dr Farberg:  Overall, the maintenance of response to tildrakizumab is great in that it's quite durable. The IL-23 inhibitors can be taken together as a class, for which many comparative studies suggest that the IL-23 inhibitors deliver a robust and long-lasting efficacy with long treatment intervals and relative safety with few contraindications.

Tildrakizumab definitely lives up to its IL-23 class for its maintenance of response. It provides lasting clearance with consistent safety. The IL-17s also have good durability, as do the TNF inhibitors, albeit, perhaps, in some cases, relatively less so.

Particular for tildrakizumab, the frequency of adverse reactions was similar to that during the placebo-controlled period with no new adverse reactions identified. Overall, tildrakizumab is very safe, and I have little concerns when prescribing it. The adverse reactions that are most likely to occur are uncomplicated upper respiratory infections and injection site reactions.

Again, tildrakizumab is a great treatment option for my psoriasis patients. The long-term safety at week 244 is comparable to that of tildrakizumab safety profile throughout the study period, including at one year, or 52 weeks. Tildrakizumab has demonstrated five years of consistent safety data.

There are fewer adverse events and serious adverse events occurred with tildrakizumab than with placebo. If you think about that, that's quite remarkable.